Xspray Pharma and Eversana sign agreement for US launch of cancer therapy
Xspray Pharma will maintain financial and strategic control and grant exclusive commercialisation access to Eversana for supporting its Dasynoc launch. Dasynoc, pending approval from the Food and Drug